MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
MiNK Therapeutics, Inc.NASDAQ: INKT
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 27.5% from a year ago
Common stock stood at $51 at the end of Q1 FY2026, up 27.5% from a year earlier and up 6.3% from the prior quarter. Over 3 fiscal years it compounded at -47.9% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +27.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 48 USD
- Year-over-year change
- +20.0%
- 4-year CAGR
- -38.5%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48 | +20.0% |
| FY2024 | 2024-12-31 | 40 | -88.4% |
| FY2023 | 2023-12-31 | 346 | +2.1% |
| FY2022 | 2022-12-31 | 339 | +1.2% |
| FY2021 | 2021-12-31 | 335 | — |
Common Stock vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's Mar 2026 common stock of $51 is the 8th highest of the 9 companies compared; the peer median is $19K.
- Its year-over-year change of +27.5% is the 6th highest of 9, against a peer median of +57.2%.
- Common stock amounts to 0.0% of total assets for INKT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.05M | +217.9% | -38.1% | 4.8% | |
OSTXOS Therapies Incorporated | Mar 2026 | $39.28K | +84.0% | +95.2% | 0.5% |
| Mar 2026 | $39K | +21.9% | +13.0% | 0.0% | |
| Mar 2026 | $33K | +94.1% | -21.8% | 0.3% | |
| Mar 2026 | $5K | +66.7% | +18.6% | 0.0% | |
| Jun 2026 | $5K | +0.0% | +18.6% | 0.0% | |
| Mar 2026 | $4.25K | +47.8% | +52.4% | 0.0% | |
| Mar 2026 | $51 | +27.5% | -47.9% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding INKT) | $19K | +57.2% | +18.6% | 0.0% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38.89M | 19.64M | 3.37M | 4.58M | 13.36M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 23K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 721.32K | 470.3K | 177.96K | 164.24K | 211.2K |
| Total Current Assets | 39.63M | 20.4M | 3.6M | 4.99M | 13.85M |
| Property, Plant & Equipment (Net) | 606.6K | 1.07M | 953.98K | 732.93K | 390.87K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 606.6K | 1.07M | 953.98K | 732.93K | 390.87K |
| Total Assets | 40.24M | 21.47M | 4.55M | 5.72M | 14.24M |
| Account Payables | 3M | 5.82M | 3.91M | 2.73M | 3.43M |
| Short-term Debt | 0 | 0 | 0 | 0 | 5.18M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.76M | 5.21M | 5.66M | 3.51M | 2.85M |
| Total Current Liabilities | 16.47M | 12.68M | 11.4M | 6.96M | 13.03M |
| Long-term Debt | 0 | 0 | 0 | 4.92M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 9.19M | 11.21M | 13.42M | 15.44M |
| Total Non-current Liabilities | 0 | 9.19M | 11.21M | 18.35M | 15.44M |
| Total Liabilities | 16.47M | 21.87M | 22.61M | 25.31M | 28.47M |
| Common Stock | 335 | 339 | 346 | 40 | 48 |
| Retained Earnings | (82.95M) | (110.94M) | (133.4M) | (144.18M) | (156.68M) |
| Accumulated OCI | (625.27K) | (292.47K) | (430.95K) | (631.58K) | (718.92K) |
| Other Stockholders Equity | 0 | 900 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 23.78M | (401.3K) | (18.06M) | (19.59M) | (14.23M) |
| Total Debt | 0 | 0 | 0 | 4.92M | 5.18M |
| Net Debt | (38.89M) | (19.64M) | (3.37M) | 347.57K | (8.18M) |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.